NASDAQ: MYNZMainz Biomed Nv Stock
$1.41-0.07 (-4.73%)
Updated Oct 16, 2025
MYNZ Price
$1.41
Fair Value Price
N/A
Market Cap
$5.77M
52 Week Low
$1.28
52 Week High
$14.39
P/E
-0.26x
P/B
2.29x
P/S
6.72x
PEG
N/A
Dividend Yield
N/A
Revenue
$659.94k
Earnings
-$18.97M
Gross Margin
67.5%
Operating Margin
-2,942.01%
Profit Margin
-2,874.7%
Debt to Equity
2.89
Operating Cash Flow
-$15M
Beta
0.85
Next Earnings
Nov 13, 2025
Ex-Dividend
N/A
Next Dividend
N/A
MYNZ Overview
Mainz Biomed NV develops in-vitro human genetics tests for clinical diagnostics. Offerings offers ColoAlert, a colorectal cancer screening test, PancAlert, a product candidate for a pancreatic cancer screening test, GenoStrip to detect pathogens in environments on a molecular genetic basis, and research-use-only and IVD tests. Mainz Biomed was founded in 2008 and is headquartered in Mainz, Germany.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine MYNZ's potential to beat the market
- MYNZ doesn't meet the minimum data requirements for our proprietary Zen Ratings model. Learn more about Zen Ratings.
Zen Rating Component Grades
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Diagnostic & Research
Industry Rating
C
MYNZ
RankedUnranked of 44
RankedUnranked of 44
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $16.33 | A | |
| $283.71 | B | |
| $174.95 | B |
Be the first to know about important MYNZ news, forecast changes, insider trades & much more!
MYNZ News
Overview
Due Diligence Score
–
Industry Average (26)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how MYNZ scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
MYNZ is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
MYNZ is good value based on its book value relative to its share price (2.29x), compared to the US Diagnostics & Research industry average (4.11x)
P/B vs Industry Valuation
MYNZ is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more MYNZ due diligence checks available for Premium users.
Valuation
MYNZ price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.26x
Industry
22.67x
Market
36.99x
MYNZ price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
2.29x
Industry
4.11x
MYNZ is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
MYNZ's financial health
Profit margin
Revenue
$0.0
Net Income
$0.0
Profit Margin
0%
MYNZ's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
MYNZ's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$9.8M
Liabilities
$7.3M
Debt to equity
2.89
MYNZ's short-term liabilities ($5.99M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
MYNZ's short-term assets ($3.09M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
MYNZ's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
N/A
Investing
N/A
Financing
N/A
MYNZ's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
MYNZ vs Diagnostic & Research Stocks
Mainz Biomed Nv Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.